Jinyou Pharmaceutical: Stock price deviation from fundamentals indicates trading and performance risks

Jinshi Pharmaceutical announced that from March 26 to April 2, 2026, the company's stock rose by the daily limit for five consecutive trading days, with a cumulative increase of 60.10%. The company's fundamentals have not changed, and its current research and development focus is on generic drugs, with no ongoing projects for innovative drugs. In the first three quarters of 2025, the company's revenue was 2.232 billion yuan, a year-on-year decrease of 13.24%; net profit was 69.5399 million yuan, a year-on-year decrease of 62.75%; and non-GAAP net profit was 136 million yuan, a year-on-year decrease of 26.06%. The company's latest P/E ratio is 424.82 times, far higher than the industry average of 29.72 times, reminding investors to pay attention to trading and performance risks.